KR20150035537A - 종양 세포 분리/정제 프로세스 및 이의 사용 방법들 - Google Patents

종양 세포 분리/정제 프로세스 및 이의 사용 방법들 Download PDF

Info

Publication number
KR20150035537A
KR20150035537A KR20147032343A KR20147032343A KR20150035537A KR 20150035537 A KR20150035537 A KR 20150035537A KR 20147032343 A KR20147032343 A KR 20147032343A KR 20147032343 A KR20147032343 A KR 20147032343A KR 20150035537 A KR20150035537 A KR 20150035537A
Authority
KR
South Korea
Prior art keywords
candidate
therapeutic agent
cells
cell
anticancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20147032343A
Other languages
English (en)
Korean (ko)
Inventor
캐리 프리전트
매튜 퍼리
알란 할퀴스트
Original Assignee
디아테크 온콜로지, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디아테크 온콜로지, 엘엘씨 filed Critical 디아테크 온콜로지, 엘엘씨
Publication of KR20150035537A publication Critical patent/KR20150035537A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00Culture process characterised by the use of mechanical forces, e.g. strain, vibration
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR20147032343A 2012-05-15 2013-03-14 종양 세포 분리/정제 프로세스 및 이의 사용 방법들 Withdrawn KR20150035537A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647248P 2012-05-15 2012-05-15
US61/647,248 2012-05-15
PCT/US2013/031300 WO2013172955A1 (en) 2012-05-15 2013-03-14 Tumor cell isolation/purification process and methods for use thereof

Publications (1)

Publication Number Publication Date
KR20150035537A true KR20150035537A (ko) 2015-04-06

Family

ID=49584132

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147032343A Withdrawn KR20150035537A (ko) 2012-05-15 2013-03-14 종양 세포 분리/정제 프로세스 및 이의 사용 방법들

Country Status (17)

Country Link
US (2) US20150160193A1 (enExample)
EP (1) EP2850434A4 (enExample)
JP (1) JP2015517662A (enExample)
KR (1) KR20150035537A (enExample)
CN (1) CN104704368A (enExample)
AU (1) AU2013263337A1 (enExample)
BR (1) BR112014028396A2 (enExample)
CA (1) CA2873180A1 (enExample)
CO (1) CO7240391A2 (enExample)
CR (1) CR20140575A (enExample)
HK (1) HK1208727A1 (enExample)
IL (1) IL235709A0 (enExample)
IN (1) IN2014DN09582A (enExample)
MX (1) MX2014013939A (enExample)
SG (1) SG11201407497TA (enExample)
TW (1) TW201409029A (enExample)
WO (1) WO2013172955A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12324657B2 (en) 2007-11-28 2025-06-10 Intervet Inc. System and method for diagnosis of bovine diseases using auscultation analysis
US9476871B2 (en) 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
EP2953544B1 (en) * 2013-02-06 2019-05-08 Intervet Inc. System for determining antibiotic effectiveness in respiratory diseased using auscultation analysis
MY189089A (en) 2013-12-17 2022-01-25 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CN116327953A (zh) 2015-06-17 2023-06-27 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
US20210011018A1 (en) * 2018-03-20 2021-01-14 Lumacyte, LLC Advanced biophysical and biochemical cellular monitoring and quantification using laser force cytology
TWI662130B (zh) * 2018-09-21 2019-06-11 國立臺灣大學 分離循環癌細胞之方法
CN111019899B (zh) * 2019-02-14 2023-08-04 中山大学孙逸仙纪念医院 人恶性叶状肿瘤细胞系lj-0429及其应用
CN111019897B (zh) * 2019-02-14 2023-08-11 中山大学孙逸仙纪念医院 人良性叶状肿瘤细胞系glk-1010及其应用
CN111019898B (zh) * 2019-02-14 2023-07-21 中山大学孙逸仙纪念医院 人恶性叶状肿瘤细胞系hjp-0320及其应用
CN113466417B (zh) * 2021-05-13 2023-03-21 柳州东风容泰化工股份有限公司 一种氟尿嘧啶的制备纯度评估方法及系统
WO2024054627A1 (en) * 2022-09-08 2024-03-14 The University Of North Carolina At Chapel Hill Diagnosis of patient tumor tissue
CN115747290A (zh) * 2022-11-23 2023-03-07 零壹人工智能科技研究院(南京)有限公司 一种对肠癌类器官进行药敏测试的新操作方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0891550A1 (en) * 1996-04-05 1999-01-20 The Johns Hopkins University School Of Medicine A method of enriching rare cells
US6077684A (en) * 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture
WO2002040702A2 (en) * 2000-11-09 2002-05-23 Vanderbilt University Methods for the treatment of cancer and other diseases and methods of developing the same
KR100721927B1 (ko) * 2006-10-31 2007-05-28 이수앱지스 주식회사 암조직에서 암세포를 분리하는 방법
IT1391619B1 (it) * 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
US20110244503A1 (en) * 2010-03-31 2011-10-06 Perree Mathieu System and Method for Anti-Cancer Drug Candidate Evaluation
BR112012024619A2 (pt) * 2010-03-31 2016-05-31 Diatech Oncology Llc sistema e método para avaliação de candidato a medicamento anticancer
US9476871B2 (en) * 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates

Also Published As

Publication number Publication date
WO2013172955A9 (en) 2014-02-27
SG11201407497TA (en) 2014-12-30
AU2013263337A1 (en) 2014-12-04
CR20140575A (es) 2015-05-07
CO7240391A2 (es) 2015-04-17
BR112014028396A2 (pt) 2018-05-29
TW201409029A (zh) 2014-03-01
EP2850434A4 (en) 2016-01-13
CA2873180A1 (en) 2013-11-21
WO2013172955A1 (en) 2013-11-21
US20170336391A1 (en) 2017-11-23
CN104704368A (zh) 2015-06-10
JP2015517662A (ja) 2015-06-22
HK1208727A1 (zh) 2016-03-11
MX2014013939A (es) 2015-05-11
IN2014DN09582A (enExample) 2015-07-17
EP2850434A1 (en) 2015-03-25
US20150160193A1 (en) 2015-06-11
IL235709A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
KR20150035537A (ko) 종양 세포 분리/정제 프로세스 및 이의 사용 방법들
Dünker et al. Implementation of the chick chorioallantoic membrane (CAM) model in radiation biology and experimental radiation oncology research
JP6782698B2 (ja) がん患者を診断および処置するためのerbbシグナル伝達経路活性の測定方法
CN103399144A (zh) 用抗体阵列选择乳腺癌治疗药物
CN109563486A (zh) 用于在癌症护理中做出患者特定的治疗决策的诊断方法
Smolle et al. T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study
Sathi et al. Analysis of immunoexpression of common cancer stem cell markers in ameloblastoma
US20230184744A1 (en) INTERTUMORAL HOMOGENEITY DETERMINED BY MiCK ASSAY
Beasley et al. Analysis of circulating tumour cells in early-stage uveal melanoma: evaluation of tumour marker expression to increase capture
Treese et al. S100A4 is a strong negative prognostic marker and potential therapeutic target in adenocarcinoma of the stomach and esophagus
Goesmann et al. Characterization and quantitation of the tumor microenvironment of uveal melanoma
Liao et al. The microRNA-210-Stathmin1 axis decreases cell stiffness to facilitate the invasiveness of colorectal cancer stem cells
Kim et al. Role of B-cell translocation gene 1 in the pathogenesis of endometriosis
Nykänen et al. Ex vivo drug screening informed targeted therapy for metastatic parotid squamous cell carcinoma
Zhao et al. Application research of individualized conditional reprogramming system to guide treatment of gastric cancer
Chen et al. Autologous Paracrine Prostasin–Matriptase Serine Protease Interaction in Lymphoid Cancer Cells
Meng et al. S100 Calcium-Binding Protein P and Cathepsin E as Key Mediators in Pancreatic Cancer Tumorigenesis
Satterlee et al. Rapid Functional Drug Screening of Passage-Zero Patient Brain Tumor Tissues Ex Vivo: Results from a Clinical Feasibility Study
Ingawale et al. Applications of liquid biopsy in translational oncology
Estrada et al. zAvatar-test—A functional precision model to personalize ovarian cancer treatments: Results from a co-clinical study
Wagstaff et al. ADAMTS15 metalloproteinase inhibits breast cancer cell migration
Taggart et al. Breast cancer knowledge among women with learning disabilities and their experiences of breast mammography
Lamers et al. Microarray based expression profiling of BRCA1 mutated human tumours using a breast-specific platform to identify a profile of BRCA1 deficiency
Zhang et al. Identifying Cell Cycle Modulators That Selectively Target ARID1A Deficiency Using High
Sneddon et al. Opticin: a potent anti-angiogenic/antiproliferative agent for breast cancer therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141118

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid